{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T07:20:06Z","timestamp":1764919206178,"version":"3.46.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T00:00:00Z","timestamp":1761350400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T00:00:00Z","timestamp":1761350400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2021-NR061451"],"award-info":[{"award-number":["RS-2021-NR061451"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"DOI":"10.1007\/s10238-025-01875-w","type":"journal-article","created":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T05:01:42Z","timestamp":1761368502000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Ligand\u2013receptor interaction profiling as a predictive biomarker for anti-PD-1 therapy response in melanoma"],"prefix":"10.1007","volume":"25","author":[{"given":"Se Yeon","family":"Seo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong-Yeon","family":"Nam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyun Ji","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4811-8895","authenticated-orcid":false,"given":"Je-Keun","family":"Rhee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,25]]},"reference":[{"key":"1875_CR1","doi-asserted-by":"crossref","unstructured":"Sahni S, Valecha G, and Sahni A. Role of anti-PD-1 antibodies in advanced melanoma: the era of immunotherapy. Cureus. 2018;10(12).","DOI":"10.7759\/cureus.3700"},{"issue":"7","key":"1875_CR2","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.3390\/biomedicines10071737","volume":"10","author":"D Kuzmanovszki","year":"2022","unstructured":"Kuzmanovszki D, et al. Anti-PD-1 monotherapy in advanced melanoma\u2014real-world data from a 77-month-long retrospective observational study. Biomedicines. 2022;10(7):1737.","journal-title":"Biomedicines"},{"key":"1875_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.731798","volume":"12","author":"J Liu","year":"2021","unstructured":"Liu J, et al. PD-1\/PD-L1 checkpoint inhibitors in tumor immunotherapy. Front Pharmacol. 2021;12:731798.","journal-title":"Front Pharmacol"},{"issue":"5","key":"1875_CR4","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1038\/s41590-022-01141-1","volume":"23","author":"AC Huang","year":"2022","unstructured":"Huang AC, Zappasodi R. A decade of checkpoint blockade immunotherapy in melanoma: understanding the molecular basis for immune sensitivity and resistance. Nat Immunol. 2022;23(5):660\u201370.","journal-title":"Nat Immunol"},{"key":"1875_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12964-020-0530-4","volume":"18","author":"R Baghban","year":"2020","unstructured":"Baghban R, et al. Tumor microenvironment complexity and therapeutic implications at a glance. Cell Commun Signal. 2020;18:1\u201319.","journal-title":"Cell Commun Signal"},{"key":"1875_CR6","doi-asserted-by":"crossref","unstructured":"Asokan S and Bandapalli OR. CXCL8 signaling in the tumor microenvironment. Tumor Microenvironment: the role of chemokines\u2013Part B, 2021; p. 25\u201339.","DOI":"10.1007\/978-3-030-62658-7_3"},{"issue":"1","key":"1875_CR7","doi-asserted-by":"publisher","first-page":"137","DOI":"10.3390\/molecules27010137","volume":"27","author":"Z-J Han","year":"2021","unstructured":"Han Z-J, et al. Roles of the CXCL8-CXCR1\/2 axis in the tumor microenvironment and immunotherapy. Molecules. 2021;27(1):137.","journal-title":"Molecules"},{"issue":"8","key":"1875_CR8","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.jacc.2009.03.076","volume":"54","author":"C Antoniades","year":"2009","unstructured":"Antoniades C, et al. The CD40\/CD40 ligand system: linking inflammation with atherothrombosis. J Am Coll Cardiol. 2009;54(8):669\u201377.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"1875_CR9","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/s41423-021-00734-4","volume":"19","author":"TN Bullock","year":"2022","unstructured":"Bullock TN. CD40 stimulation as a molecular adjuvant for cancer vaccines and other immunotherapies. Cell Mol Immunol. 2022;19(1):14\u201322.","journal-title":"Cell Mol Immunol"},{"issue":"9","key":"1875_CR10","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/S0161-5890(00)00079-1","volume":"37","author":"AB Alexandroff","year":"2000","unstructured":"Alexandroff AB, et al. Role for CD40\u2013CD40 ligand interactions in the immune response to solid tumours. Mol Immunol. 2000;37(9):515\u201326.","journal-title":"Mol Immunol"},{"issue":"12","key":"1875_CR11","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1038\/s41591-019-0654-5","volume":"25","author":"D Liu","year":"2019","unstructured":"Liu D, et al. Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma. Nat Med. 2019;25(12):1916\u201327.","journal-title":"Nat Med"},{"issue":"12","key":"1875_CR12","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1007\/s13238-020-00727-5","volume":"11","author":"X Shao","year":"2020","unstructured":"Shao X, et al. New avenues for systematically inferring cell-cell communication: through single-cell transcriptomics data. Protein Cell. 2020;11(12):866\u201380.","journal-title":"Protein Cell"},{"issue":"1","key":"1875_CR13","doi-asserted-by":"publisher","DOI":"10.1093\/nargab\/lqad030","volume":"5","author":"MR Vahid","year":"2023","unstructured":"Vahid MR, et al. Disir: fast and robust method to identify ligand\u2013receptor interactions at subunit level from single-cell RNA-sequencing data. NAR Genom Bioinform. 2023;5(1):lqad030.","journal-title":"NAR Genom Bioinform"},{"issue":"12","key":"1875_CR14","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1248\/bpb.b22-00295","volume":"45","author":"Y Jing","year":"2022","unstructured":"Jing Y, et al. TLR9 exerts an oncogenic role in promoting osteosarcoma progression depending on the regulation of NF-\u03baB signaling pathway. Biol Pharm Bull. 2022;45(12):1733\u201342.","journal-title":"Biol Pharm Bull"},{"issue":"1","key":"1875_CR15","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3390\/antib13010008","volume":"13","author":"MH Ravindranath","year":"2024","unstructured":"Ravindranath MH, et al. Diversity in the HLA-I recognition of HLA-F monoclonal antibodies: HLA-F or HLA-Ib monospecific, HLA-E or HLA-G bispecific antibodies with or without HLA-Ia reactivity. Antibodies. 2024;13(1):8.","journal-title":"Antibodies"},{"issue":"1","key":"1875_CR16","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/s42003-022-03370-4","volume":"5","author":"S-B Ko","year":"2022","unstructured":"Ko S-B, et al. Functional role of the Frizzled linker domain in the Wnt signaling pathway. Commun Biol. 2022;5(1):421.","journal-title":"Commun Biol"},{"key":"1875_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12964-021-00708-z","volume":"19","author":"D Dong","year":"2021","unstructured":"Dong D, et al. FZD5 prevents epithelial-mesenchymal transition in gastric cancer. Cell Commun Signal. 2021;19:1\u201313.","journal-title":"Cell Commun Signal"},{"issue":"2","key":"1875_CR18","first-page":"161","volume":"122","author":"X Ou","year":"2013","unstructured":"Ou X, O\u2019Leary HA, Broxmeyer HE. Implications of DPP4 modification of proteins that regulate stem\/progenitor and more mature cell types. Blood, Journal Am Soc Hematol. 2013;122(2):161\u20139.","journal-title":"Blood, Journal Am Soc Hematol"},{"key":"1875_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12935-021-02226-x","volume":"21","author":"M Deng","year":"2021","unstructured":"Deng M, et al. EFNA3 as a predictor of clinical prognosis and immune checkpoint therapy efficacy in patients with lung adenocarcinoma. Cancer Cell Int. 2021;21:1\u201317.","journal-title":"Cancer Cell Int"},{"key":"1875_CR20","doi-asserted-by":"publisher","first-page":"1228889","DOI":"10.3389\/fonc.2023.1228889","volume":"13","author":"M He","year":"2023","unstructured":"He M, et al. Upregulated FADD is associated with poor prognosis, immune exhaustion, tumor malignancy, and immunotherapy resistance in patients with lung adenocarcinoma. Front Oncol. 2023;13:1228889.","journal-title":"Front Oncol"},{"issue":"12","key":"1875_CR21","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1158\/2159-8290.CD-15-1347","volume":"6","author":"BV Park","year":"2016","unstructured":"Park BV, et al. TGF\u03b21-mediated SMAD3 enhances PD-1 expression on antigen-specific T cells in cancer. Cancer Discov. 2016;6(12):1366\u201381.","journal-title":"Cancer Discov"},{"issue":"4","key":"1875_CR22","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.ccell.2020.08.005","volume":"38","author":"CS Grasso","year":"2020","unstructured":"Grasso CS, et al. Conserved interferon-\u03b3 signaling drives clinical response to immune checkpoint blockade therapy in melanoma. Cancer cell. 2020;38(4):500-515e3.","journal-title":"Cancer cell"},{"issue":"2","key":"1875_CR23","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1158\/1078-0432.CCR-19-1868","volume":"26","author":"IG House","year":"2020","unstructured":"House IG, et al. Macrophage-derived CXCL9 and CXCL10 are required for antitumor immune responses following immune checkpoint blockade. Clin Cancer Res. 2020;26(2):487\u2013504.","journal-title":"Clin Cancer Res"},{"issue":"11","key":"1875_CR24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0207255","volume":"13","author":"V Juric","year":"2018","unstructured":"Juric V, et al. MMP-9 inhibition promotes anti-tumor immunity through disruption of biochemical and physical barriers to T-cell trafficking to tumors. PLoS One. 2018;13(11):e0207255.","journal-title":"PLoS One"},{"key":"1875_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2024.03.031","author":"M-P St-Laurent","year":"2024","unstructured":"St-Laurent M-P, Black PC. Re: FGFR inhibition augments anti-PD-1 efficacy in murine FGFR3-mutant bladder cancer by abrogating immunosuppression. Eur Urol. 2024. https:\/\/doi.org\/10.1016\/j.eururo.2024.03.031.","journal-title":"Eur Urol"},{"issue":"12","key":"1875_CR26","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1158\/2326-6066.CIR-23-0139","volume":"11","author":"DY Torrejon","year":"2023","unstructured":"Torrejon DY, et al. Antitumor immune responses in B2M-deficient cancers. Cancer Immunol Res. 2023;11(12):1642\u201355.","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"1875_CR27","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/s41467-023-36062-6","volume":"14","author":"B Ru","year":"2023","unstructured":"Ru B, et al. Estimation of cell lineages in tumors from spatial transcriptomics data. Nat Commun. 2023;14(1):568.","journal-title":"Nat Commun"},{"issue":"4","key":"1875_CR28","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1007\/s10456-018-9625-6","volume":"21","author":"MM Brandt","year":"2018","unstructured":"Brandt MM, et al. Endothelial loss of Fzd5 stimulates PKC\/Ets1-mediated transcription of Angpt2 and Flt1. Angiogenesis. 2018;21(4):805\u201321.","journal-title":"Angiogenesis"},{"issue":"1","key":"1875_CR29","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/2045-824X-4-13","volume":"4","author":"AC Newman","year":"2012","unstructured":"Newman AC, Hughes CC. Macrophages and angiogenesis: a role for Wnt signaling. Vasc Cell. 2012;4(1):13.","journal-title":"Vasc Cell"},{"issue":"11","key":"1875_CR30","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.3390\/cells8111380","volume":"8","author":"M Haseeb","year":"2019","unstructured":"Haseeb M, et al. Wnt signaling in the regulation of immune cell and cancer therapeutics. Cells. 2019;8(11):1380.","journal-title":"Cells"},{"issue":"1","key":"1875_CR31","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s10238-023-01274-z","volume":"24","author":"K Mortezaee","year":"2024","unstructured":"Mortezaee K. WNT\/\u03b2-catenin regulatory roles on PD-(L) 1 and immunotherapy responses. Clin Exp Med. 2024;24(1):15.","journal-title":"Clin Exp Med"},{"issue":"1","key":"1875_CR32","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/1471-2105-8-25","volume":"8","author":"C Strobl","year":"2007","unstructured":"Strobl C, et al. Bias in random forest variable importance measures: illustrations, sources and a solution. BMC Bioinformatics. 2007;8(1):25.","journal-title":"BMC Bioinformatics"},{"issue":"1","key":"1875_CR33","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1186\/s40425-019-0768-9","volume":"7","author":"AA Davis","year":"2019","unstructured":"Davis AA, Patel VG. The role of PD-L1 expression as a predictive biomarker: an analysis of all US food and drug administration (FDA) approvals of immune checkpoint inhibitors. J Immunother Cancer. 2019;7(1):278.","journal-title":"J Immunother Cancer"},{"issue":"8","key":"1875_CR34","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1038\/s41388-020-01611-6","volume":"40","author":"JE Grossman","year":"2021","unstructured":"Grossman JE, et al. Is PD-L1 a consistent biomarker for anti-PD-1 therapy? The model of balstilimab in a virally-driven tumor. Oncogene. 2021;40(8):1393\u20135.","journal-title":"Oncogene"},{"issue":"11","key":"1875_CR35","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1080\/14728222.2021.2011859","volume":"25","author":"N Silvestris","year":"2021","unstructured":"Silvestris N, et al. PD-L1 and Notch as novel biomarkers in pancreatic sarcomatoid carcinoma: a pilot study. Expert Opin Ther Targets. 2021;25(11):1007\u201316.","journal-title":"Expert Opin Ther Targets"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01875-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-025-01875-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01875-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T06:48:45Z","timestamp":1764917325000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-025-01875-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,25]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1875"],"URL":"https:\/\/doi.org\/10.1007\/s10238-025-01875-w","relation":{},"ISSN":["1591-9528"],"issn-type":[{"type":"electronic","value":"1591-9528"}],"subject":[],"published":{"date-parts":[[2025,10,25]]},"assertion":[{"value":"2 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"327"}}